The study, led by Zihang Tong and colleagues at the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, pooled evidence from 96 randomized controlled trials encompassing 18,419 adult participants. The research team searched PubMed, the Cochrane Library, Embase, and Web of Science through October 2025, then used network meta-analysis — a statistical framework that combines both direct comparisons between treatments and indirect comparisons linked through a common control — to rank six digital interventions: digital cognitive behavioral therapy (dCBT), digital mindfulness-based therapy (dMBT), digital brief behavioral therapy (dBBT), circadian rhythm support (CRS), virtual reality (VR), and tele-neurofeedback (NFB). By folding every trial into a single evidence network anchored on a shared control node, the method allows treatments never tested against each other in the same trial to be compared with remarkable statistical efficiency.

The headline finding concerns the Insomnia Severity Index, or ISI, a seven-item questionnaire that scores insomnia symptoms from 0 to 28. Compared with control treatment, dCBT reduced ISI scores by an average of 4.24 points, with a 95 percent confidence interval of −4.83 to −3.65 — an estimate supported by moderate-certainty evidence under the CINeMA framework. That figure is not just statistically significant; it crosses the minimal clinically important difference, the threshold — set at 4 points for the ISI in this analysis — beyond which patients and clinicians should actually notice a change. In other words, dCBT is the only intervention in the network whose effect on the core outcome of insomnia severity was unambiguously meaningful for real patients.

The detailed picture across other outcomes is more nuanced. dCBT also significantly improved PSQI scores (a reduction of 2.28 points), shortened subjective sleep onset latency by about 12.6 minutes, raised subjective sleep efficiency by 7.27 percentage points, and cut subjective wake after sleep onset by roughly 17.2 minutes. Yet none of these secondary effects reached their respective minimal clinically important differences, which the authors defined as, for example, at least a 3-point PSQI change or a 20-minute reduction in latency. Digital mindfulness-based therapy produced a smaller but significant ISI reduction of 2.28 points and shortened objectively measured sleep onset latency by 7.96 minutes, the latter based on moderate-certainty evidence from polysomnography and actigraphy studies. Virtual reality, evaluated through an inconsistency model because of statistical heterogeneity, reduced objectively measured wake after sleep onset by 13.38 minutes — significant, but again below the clinical threshold.

Direct head-to-head comparisons within the network reinforced dCBT’s dominance. It outperformed dMBT on the ISI (by 1.96 points) and on subjective total sleep time (by about 10 minutes), beat VR on the PSQI, and surpassed circadian rhythm support on sleep latency and sleep efficiency measures. Using SUCRA statistics, which express the probability that a treatment ranks best, dCBT topped the charts for the ISI (93.3 percent), the PSQI (95.8 percent), subjective sleep onset latency (95.0 percent), and subjective sleep efficiency (93.0 percent). Three interventions — tele-neurofeedback, digital brief behavioral therapy, and circadian rhythm support — showed no statistically significant benefits over control for any outcome, effectively dropping out of the clinical conversation until better evidence emerges.

The authors went well beyond the headline averages. Subgroup analyses probed whether effects differed by control group type, therapist guidance, treatment duration, and population. Notably, dCBT performed as well as face-to-face CBT where such comparisons existed, held up against active controls rather than only passive waitlists, and worked whether delivered with a therapist in the loop or fully automated — the ISI effect was −4.48 points with guidance versus −4.10 points without, a gap of less than half a point. Treatment duration mattered little for the core outcome: the ISI effect was identical (−4.24 points) whether programs ran eight weeks or longer. Effects were somewhat larger in people with insomnia symptoms who lack a formal diagnosis than in diagnosed patients, suggesting those with less entrenched sleep pathology may respond more readily to structured digital programs.

Sensitivity analyses added important caveats about who benefits. dCBT’s effects proved stable across pregnant women, cancer patients, and people with depression or anxiety, indicating broad applicability. dMBT’s efficacy, by contrast, appeared inflated in pregnant women under certain control designs and weaker in cancer survivors, and its improvement on the PSQI was fragile among depressed patients. VR was the most volatile intervention of all: its estimated effects swung dramatically depending on which small studies were included, leading the authors to urge caution about deploying VR in oncology, acute medical settings, and populations with severe somatic disease.

The study is candid about its limitations, and readers should absorb them. Only two of the 96 trials were judged low risk of bias overall, with 94 showing some concerns — especially around outcome measurement, where participants inevitably know what treatment they are receiving, inflating expectancy effects on subjective questionnaires. Heterogeneity was high for the ISI and PSQI, objective sleep outcomes rested on few trials with small samples, roughly 40 trials had potential industry funding, and the analysis captured only immediate post-treatment results with no follow-up data on whether benefits persist. The treatment taxonomy also followed a Chinese expert consensus rather than international regulatory frameworks, which may limit direct comparability with other classification schemes.

Still, the practical implications are hard to escape. For clinicians building insomnia care pathways, the evidence reasonably supports dCBT as the primary digital option, given its clinically meaningful reduction in insomnia severity. dMBT emerges as a reasonable alternative or adjunct — particularly for patients who prefer mindfulness approaches or struggle to adhere to CBT — even though its benefits did not reach clinical significance thresholds. The absence of patient and public involvement in the analysis, the authors acknowledge, means real-world preferences around acceptability remain underexplored. What the study delivers is something prior reviews could not: a single network in which six different digital therapies, from smartphone-delivered CBT to immersive VR, compete on equal statistical footing to answer the question patients actually ask — which one is best.

The research team, funded by Tianjin science and health programs and registered prospectively on PROSPERO, concludes that future work should prioritize large-scale, high-quality randomized trials with standardized interventions, objective outcome frameworks, and long-term follow-up. Until then, this analysis stands as the most complete map of the digital sleep-therapy landscape — one that confirms the promise of treatment delivered by app, but also warns that statistical significance alone is not the same as a patient sleeping meaningfully better. For the 16.2 percent of adults worldwide reporting clinically significant insomnia, the difference between those two thresholds is exactly the kind of precision that evidence-based medicine is meant to provide.

Subject of Research: Comparative effectiveness of digital therapeutics for improving sleep quality in adults with insomnia

Article Title: The effectiveness of digital therapeutics in improving sleep quality: a systematic review and network meta-analysis

Article References: Tong, Z., Ye, G., Fan, S., Li, Y., Zhang, J., Zhang, H., Chen, Q., Wang, H., Li, H., & Wang, J. (2026). The effectiveness of digital therapeutics in improving sleep quality: a systematic review and network meta-analysis. BMC Medicine, 24(1), Article 526. https://doi.org/10.1186/s12916-026-05129-8

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05129-8

Keywords: digital therapeutics, insomnia, sleep quality, network meta-analysis, digital cognitive behavioral therapy, mindfulness, virtual reality, tele-neurofeedback, circadian rhythm support, randomized controlled trials, PSQI, Insomnia Severity Index

Negative symptoms represent one of the most challenging dimensions of schizophrenia. Unlike positive symptoms such as hallucinations and delusions, which involve the presence of abnormal experiences, negative symptoms involve the absence or diminution of normal functioning. These include avolition, or a reduced drive to initiate and sustain goal-directed activity, anhedonia, or a diminished capacity to experience pleasure, asociality, blunted affect, and poverty of speech. For many patients, these symptoms persist even when antipsychotic medications successfully control hallucinations and delusions, and they are strongly linked to social isolation, unemployment, and reduced quality of life.

The scarcity of effective treatments for negative symptoms has long frustrated clinicians and researchers. Most antipsychotic drugs, which primarily act on dopamine systems to suppress positive symptoms, offer little benefit for motivational and pleasure deficits. Psychosocial approaches such as cognitive behavioral therapy and social skills training can help, but their effects are often modest, and access to trained therapists remains a barrier in many health systems. This treatment gap has made the development of scalable, evidence-based interventions for negative symptoms a major priority in mental health research.

CT-155 was developed as a digital therapeutic, a class of software-based interventions intended to deliver therapeutic benefit through structured engagement, often on a computer or tablet. Digital therapeutics differ from general wellness apps in that they are designed to be evaluated in clinical trials with the same rigor expected of medical treatments, measuring safety and efficacy against defined endpoints. In this trial, the intervention was tested specifically against motivation and pleasure negative symptoms, the domain that most directly shapes a patient’s ability to pursue goals, enjoy daily activities, and maintain social connections.

The randomized clinical trial design is the gold standard for determining whether an intervention produces genuine benefit beyond placebo effects or the natural course of a condition. By randomly assigning participants to receive either the digital therapeutic or a comparator, researchers can isolate the specific contribution of the active intervention. In this study, the trial demonstrated that CT-155 improved motivation and pleasure negative symptoms to a degree the investigators characterized as small to moderate. While such effect sizes may sound modest, in psychiatry they are consistent with the magnitude of benefit typically observed for approved psychosocial interventions and pharmacologic treatments, which underscores the clinical relevance of the finding.

Safety and tolerability are equally critical considerations for any new schizophrenia treatment, particularly because patients often take multiple medications and may be sensitive to side effects. The trial reported that CT-155 was well tolerated and safe, an outcome that is notable for a software-based intervention that does not add pharmacologic burden. Because the therapy works through structured digital engagement rather than drug action on brain chemistry, it can in principle be combined with existing antipsychotic regimens without concerns about drug-drug interactions, supporting its proposed role as an adjunctive therapy rather than a replacement for medication.

The corresponding author of the study is Abhishek Pratap, PhD, of Global Clinical Development Mental Health and Eye Health at Boehringer Ingelheim Pharmaceuticals Inc, indicating that the intervention emerged from an industrial research and development program focused on mental health. The involvement of a major pharmaceutical company reflects a broader trend in which drug developers are expanding into digital and combination approaches, recognizing that software-delivered interventions can address aspects of psychiatric illness that molecules alone have failed to reach.

Perhaps the most consequential implication of the finding is scalability. Traditional psychosocial interventions for schizophrenia require trained clinicians, scheduled sessions, and institutional infrastructure, all of which limit how many patients can be reached. A digital therapeutic, once validated and deployed, can in principle be distributed widely and used with far fewer constraints on clinician time and geography. The authors suggest that CT-155 may represent a scalable, accessible option for improving schizophrenia negative symptoms, a claim that carries significant weight for health systems struggling to meet the demand for mental health care.

At the same time, the small-to-moderate effect size is a reminder that digital therapeutics are not a cure and that real-world performance can differ from trial conditions. Questions about long-term durability of benefit, adherence over months and years of use, and effectiveness across diverse patient populations will shape how such interventions are ultimately integrated into care. Digital interventions also depend on patients engaging with the software, and motivation is precisely the faculty impaired by negative symptoms, a challenge that the design of the therapy must address for sustained benefit.

Nevertheless, the trial marks a meaningful step forward in a field where genuine treatment advances for negative symptoms have been rare. Published in JAMA Network Open, a peer-reviewed journal, the study adds to a growing body of evidence that carefully engineered digital interventions can produce clinically measurable improvements in serious mental illness. For the millions of people worldwide living with schizophrenia, many of whom face persistent motivational and pleasure deficits that medications do not relieve, a safe, well-tolerated, and scalable adjunctive therapy offers a reason for cautious optimism and a signal of where psychiatric treatment may be heading.

Subject of Research: A randomized clinical trial of the digital therapeutic CT-155 for negative symptoms of schizophrenia

Article Title: A digital therapeutic intervention for negative symptoms of schizophrenia

Article References: A digital therapeutic intervention for negative symptoms of schizophrenia. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: schizophrenia, negative symptoms, digital therapeutics, CT-155, randomized clinical trial, JAMA Network Open, motivation and pleasure deficits, psychiatry, mental health, Boehringer Ingelheim, adjunctive therapy, avolition

In the study, a team of researchers from King’s College London, the University of Padova and Orygen at the University of Melbourne asked 71 patients with anorexia nervosa to complete a single five-minute exposure session inside a virtual kitchen. The scenario, delivered through a head-mounted display, presented a domestic kitchen stocked with foods of varying calorie contents, including many of the items patients most commonly avoid. The researchers were interested not only in whether the virtual environment could provoke realistic anxiety, but in how patients felt about the experience itself. To capture this, each participant took part in an individual semi-structured interview immediately after the exposure session, and the resulting transcripts were analysed thematically to identify recurring patterns in what patients valued, feared and wanted changed.

The study was designed as a randomised comparison of three versions of the virtual kitchen. Twenty-four participants experienced the kitchen alone, without any additional elements. Twenty-five were exposed to the kitchen alongside a virtual pet, described in the plain-language summary of the study as a pink elephant, intended to induce positive mood during the exposure. A further twenty-two encountered the kitchen together with an avatar that delivered a motivational message while the patient faced the threatening foods. These two additions were grounded in psychological theory: positive affect can broaden thinking and reduce defensive avoidance, while supportive communication from another person, even a virtual one, may lower the perceived social pressure that often surrounds eating situations in anorexia nervosa.

Thematic analysis of the interviews revealed four major themes. The first and perhaps most consequential was that patients regarded virtual reality as a credible and useful tool for exploring and changing their food-related difficulties. Rather than dismissing the virtual kitchen as a gimmick, participants described it as a safe bridge between the consulting room and the real world, a space where they could approach feared foods knowing that nothing they touched would actually be eaten, weighed or photographed. This sense of psychological safety did not eliminate anxiety, and the researchers did not intend it to. Instead, the environment elicited what the authors describe as tolerable levels of anxiety: enough emotional activation to make exposure meaningful, but not so much that patients disengaged or refused the task entirely. From a clinical standpoint, that balance is precisely what effective exposure requires, and it echoes the inhibitory learning model on which modern exposure treatments are built.

The second theme centred on personalisation. Participants did not want a one-size-fits-all kitchen; they wanted environments that reflected their own triggers, histories and stage of recovery. Their suggestions were detailed and practical: a choice of foods so that each person could work with items they genuinely feared rather than generic stand-ins, the ability to include environments that were personally challenging, and more opportunities to interact with the objects in the scene. Several participants proposed a virtual eating feature, which would allow them to rehearse the full sequence of approaching, selecting and consuming a feared food within the simulation before attempting it in reality. Others asked for a human-like avatar, suggesting that the current virtual figure did not fully carry the social qualities that make support feel genuine. These requests matter because personalisation is increasingly understood as a driver of engagement in digital therapeutics, and patients with eating disorders are notoriously prone to dropping out of treatments that feel irrelevant or coercive.

The third and fourth themes addressed the two experimental additions directly. The avatar and its motivational message were broadly acceptable, with patients valuing the idea of social support during exposure, though several argued that the message should be delivered before the exposure begins rather than during it, so that encouragement does not interrupt the very process of confronting and tolerating anxiety. The virtual pet, meanwhile, met with general enthusiasm. Patients welcomed the playful, warm presence of an animal companion, and many felt it lightened the emotional tone of the session without trivialising the task. The pet’s contribution to positive mood appeared to make the kitchen feel less clinical and more like a space the patient could inhabit at their own pace, which aligns with the study’s aim of testing whether mood-inducing elements can enhance inhibitory learning of food-related anxiety and avoidance.

Technically, the study illustrates why virtual reality is attractive for exposure-based treatments. A virtual kitchen can be generated once and deployed infinitely, ensuring that every patient encounters a consistent, controllable stimulus hierarchy that would be impractical to replicate with real food. Calorie content, packaging, quantity and placement of foods can be varied systematically across sessions, allowing therapists to grade exposure precisely as the patient progresses. The environment can also be safely repeated: a patient who becomes overwhelmed can step out instantly, and a patient who succeeds can return the next day without the logistical burden of shopping, preparation and waste. For conditions such as anorexia nervosa, where foods themselves carry intense symbolic and emotional charge, the ability to rehearse difficult situations with real consequences suspended is a genuine therapeutic advantage.

The qualitative design also highlights something that quantitative outcome measures often miss: the texture of patient experience. Participants described the headset environment as immersive enough to feel real, and their reported emotions suggested that the brain treats a convincing virtual kitchen much as it treats an actual one, activating the same fears and avoidance urges that clinicians hope to target. At the same time, patients maintained an awareness that they were in a simulation, which paradoxically enabled them to stay in the feared situation longer. This dual state, genuine emotional engagement held together with a background sense of safety, is exactly what researchers in cyberpsychology have proposed makes virtual reality a powerful middle ground between imagination-based exposure, which many patients struggle to sustain, and in vivo exposure, which many refuse to begin.

The findings come with appropriate caveats. The exposure sessions were brief and single-shot, and the study captured acceptability and feasibility rather than clinical efficacy; it remains to be shown whether repeated virtual kitchen sessions translate into reduced anxiety and avoidance around real food, and ultimately into better weight restoration and recovery. The sample was drawn from specialist eating disorder services, so responses among patients with less severe illness or in different care settings may differ. Nevertheless, the consistency of the four themes across 71 interviews, and the richness of the improvement suggestions, give the results a persuasive ecological validity. The study was funded by the Medical Research Council and supported by the Italian Ministry of Education and the National Institute for Health Research Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and King’s College London.

What emerges most clearly is a message that resonates beyond eating disorder care: digital therapeutics succeed when patients are treated as co-designers rather than passive recipients. The participants in this study did not merely tolerate the virtual kitchen; they critiqued it, refined it and envisioned versions of it that might serve them better. Their collective verdict, that virtual food exposure is credible, acceptable and worth personalising, suggests that the road from laboratory simulation to routine clinical tool is shortening. If future trials confirm that these virtual kitchens help patients build more positive relationships with food, the headset may become as familiar a fixture of eating disorder treatment as the therapy room itself.

Subject of Research: Patients' experiences of virtual reality food exposure therapy in anorexia nervosa

Article Title: Patients’ experiences of virtual food exposure: a qualitative study of individual semi-structured interviews

Article References: Rowlands, K., Natali, L., Yu, P. H. M., Treasure, J., Valmaggia, L., Di Pietro, J., & Cardi, V. (2026). Patients’ experiences of virtual food exposure: a qualitative study of individual semi-structured interviews. Journal of Eating Disorders. https://doi.org/10.1186/s40337-026-01739-y

Image Credits: AI Generated

DOI: 10.1186/s40337-026-01739-y

Keywords: anorexia nervosa, virtual reality, food exposure, eating disorders, exposure therapy, digital therapeutics, anxiety, avatar, positive mood induction, qualitative research, personalisation, cyberpsychology

The replacement question, the study suggests, treats psychological care as if it were a single activity that could be performed either by a person or by a machine. In reality, someone seeking help may need many different things at once: distress that is understood without being reduced too quickly to a label, practical support to change patterns of avoidance or sleep, a relationship in which speaking feels possible, time to remain with experiences that are not yet fully nameable, a fresh account of what has happened to them, and connections to schools, workplaces, welfare services, medical care, or community support. These forms of work overlap, but they are not identical, and AI enters each of them in different ways.

To capture this complexity, the study drew on a systematic analysis of the review literature. PubMed/MEDLINE and Scopus were searched for English-language reviews combining terms for mental health, AI technologies, and review research. After deduplication, 267 reviews met eligibility conditions and formed a candidate pool. Using predefined adequacy criteria, nine reviews were selected as the initial derivation corpus. From each, the researcher extracted five elements linked to a specific table, passage, or primary study: input, AI transformation, output, immediate recipient, and affected action. These operation anchors were then split into elementary relations, each representing one output changing one immediate action for one recipient, yielding 84 relations in the initial corpus.

The comparison of these relations, organized by the action that changed immediately after an AI output rather than by technology name, produced twelve first-order operation clusters. Ten of them reached a direct action by a service user or care provider, covering current-state detection, future prediction, information extraction and summarization, interpretive inquiry, care planning, structured therapeutic activity, responsive support, provider augmentation, self-management scaffolding, and access or referral coordination. Two clusters remained at the research boundary of pattern discovery and model development. Focused reviews were then added to test four contested boundaries, expanding the final map to 69 anchors and 98 relations without requiring any additional clusters.

From this evidence map, six clinical functions were derived: assessment and case formulation; structured intervention and change support; relational responsiveness; holding unresolved experience; narrative and meaning formation and revision; and contextual and institutional connection. Each function was tested by removal and merger procedures. Removing any single candidate left distinctive objects or failures unexplained, and merging adjacent candidates erased clinically important differences, for example between understanding and action, or between intervention and institutional connection. Leave-one-review-out checks confirmed that every function remained supported by relations from multiple reviews.

The functions reveal tensions that individual performance metrics obscure. Assessment may produce a score or diagnostic candidate that supports communication and access, yet a self-diagnosis formed from social media or chatbot responses can fix a label into a person’s self-understanding before adequate evaluation. Structured interventions can deliver psychoeducation and exercises at scale, but a behavioral activation prompt may support one person and burden another, and cognitive reframing may be inappropriate when the central problem is violence, discrimination, or unsafe work. Relational responsiveness requires that someone remains answerable for the effects of a response; a chatbot may generate fluent, empathic-sounding replies without carrying responsibility for a missed crisis, growing dependency, or follow-up after a break in contact.

Across these functions, the study proposes a cross-cutting risk it calls premature stabilization. AI does not work on distress directly; it transforms experience into scores, risk categories, intervention targets, conversation summaries, or service destinations. Such provisional representations are useful scaffolds for judgment and action, but they can be stored, repeated, and transferred across settings, gradually acquiring clinical and technical authority. The danger is not rapid judgment itself but the closure of alternative formulations, narratives, relations, or pathways of support before closure is clinically warranted. A workplace wellness application that identifies elevated anxiety and suggests breathing exercises and self-checks offers genuine relief, yet it may also frame a situation shaped by exhausting workloads, intimidating supervision, and job insecurity as purely a problem of anxiety management.

As a normative response, the study advances reconfigurative care, a principle requiring two things simultaneously: that judgments and actions needed now, including diagnosis, risk assessment, intervention, and referral, remain possible, and that the representations used in those judgments stay revisable in response to new information, the person’s disagreement, changes in relationship, and the outcomes of support. This openness is not unlimited ambiguity. A risk score may justify immediate safety action, and a diagnosis may provide recognition and access. The question is whether these forms of stabilization become final too early, and whether the first form in which a person becomes institutionally legible can be questioned and replaced by another account and pathway when necessary.

Human responsibility, on this account, has interpretive, temporal, and institutional dimensions. Interpretive responsibility means treating automated classifications and summaries as materials for inquiry rather than self-explanatory facts, reading them alongside a person’s history, body, relationships, culture, and living conditions. Temporal responsibility means protecting time in which uncertain experience can remain open, without delaying action when safety demands it. Institutional responsibility means connecting distress to appropriate health, welfare, school, workplace, or community support while specifying who remains accountable after handoff. Revision is incomplete if a changed interpretation cannot change the support pathway, and referral is not accountable if it ignores the person’s meaning and timing.

Because this responsibility cannot rest on individual vigilance alone, the study argues that organizations must specify who reviews AI outputs, where a service user’s disagreement is recorded, when a case returns to human reassessment, and who assumes responsibility after referral or escalation. Training should include the practice of contextualizing outputs and reconsidering them with the person. In crisis pathways, automated detection must connect to accountable human escalation rather than end as an isolated response. The author notes the analysis is limited to English-language reviews and does not estimate the accuracy or safety of individual technologies, and that the six functions remain an interpretive framework rather than independently validated empirical categories. Still, the central conclusion stands: the value of AI in mental health care should be judged not only by the performance of individual outputs but by the clinical work and responsibilities preserved across the entire care pathway.

Subject of Research: A conceptual framework of clinical functions and responsibility in AI-mediated psychological care

Article Title: Reconfigurative care and clinical responsibility in AI-mediated psychological care ecosystems

Article References: Minami, U. (2026). Reconfigurative care and clinical responsibility in AI-mediated psychological care ecosystems. SSM – Mental Health, 10, Article 100703. https://doi.org/10.1016/j.ssmmh.2026.100703

Image Credits: AI Generated

DOI: 10.1016/j.ssmmh.2026.100703

Keywords: artificial intelligence, mental health care, psychological care, chatbots, clinical responsibility, care pathways, digital therapeutics, risk prediction, case formulation, narrative meaning, reconfigurative care, care ecosystem

The scope of the problem the issue addresses is considerable. Veterans experience elevated rates of a cluster of mental and behavioral health conditions, including posttraumatic stress disorder, chronic pain, sleep disturbances, substance use disorders, and heightened suicide risk. Alongside these well-recognized burdens sit more conventional chronic diseases that appear at higher rates in veteran populations than among civilian peers: asthma, cancer, chronic obstructive pulmonary disease, diabetes mellitus, and rheumatoid arthritis. National surveillance data cited by the editors indicate that veterans are more likely than nonveterans to live with multiple chronic conditions simultaneously, a pattern that turns routine clinical management into a complex balancing act involving behavioral, pharmacological, and social interventions.

Suicide prevention emerges as one of the most urgent threads running through the issue. Meta-analytic work on military and veteran populations has catalogued an extensive set of risk factors for suicidal ideation, attempts, and death, and the new studies extend that picture in a strikingly relational direction. One investigation of post-9/11 veterans found that parental well-being during the transition from military service to civilian life predicted veterans’ own suicidal ideation, suggesting that family-level variables belong alongside individual clinical factors in suicide risk assessment. Another study evaluated problem-solving therapy delivered within the Department of Veterans Affairs’ Suicide Prevention 2.0 clinical telehealth program, testing whether a structured cognitive intervention can reduce suicide-related outcomes when delivered remotely. Together, these contributions illustrate a shift in the field toward combining precision in risk prediction with scalable, technology-enabled delivery of care.

The military-to-civilian transition itself is treated as a critical behavioral window. Longitudinal research has documented the emergence of probable posttraumatic stress disorder among US veterans across the transition period, and the special issue includes an analysis of young adult veterans’ readjustment patterns following discharge, identifying predictors that could guide early intervention before problems consolidate into chronic conditions. A parallel qualitative and epidemiological literature on service members with service-connected disabilities shows that the transition is not a single event but an extended process shaped by employment, housing, social networks, and access to health care. For behavioral medicine, the implication is that prevention efforts timed to the months surrounding separation from service may yield disproportionate returns, a conclusion that several of the issue’s authors argue should reshape how screening and outreach are organized.

Chronic pain receives sustained attention throughout the collection, reflecting its status as one of the most common and disabling conditions in veteran care. One study documented that co-occurring chronic pain and PTSD is widespread among US military veterans and is associated with worse functioning, and the issue builds directly on that foundation with new work on women veterans, whose pain experiences are analyzed through mixed methods that capture the relational demands—caregiving, family obligations, and social expectations—that shape how pain is lived and managed. Another pair of studies followed combat veterans over time, finding that physical and emotional distress tolerance predict pain intensity and pain-related disability, and that gender, headache frequency, and headache intensity forecast psychosocial functioning and quality of life. A further analysis linked neuropathic and nociplastic pain conditions to health behaviors and mental health in veterans with type 2 diabetes, underscoring how pain, metabolic disease, and psychological distress intertwine.

Because pain and trauma so often co-occur, the issue also tackles the clinical question of how to treat both at once. A Delphi study—a structured consensus method in which expert panels iterate toward agreement—offers guidance for the simultaneous treatment of chronic pain and PTSD, an area where clinicians have historically lacked clear protocols. On the trauma side, a separate trial examined the process of prolonged exposure therapy for PTSD, finding that graduated exposure to traumatic events decreased distress during treatment, evidence that careful pacing of exposure can make one of the most effective available psychotherapies more tolerable without blunting its benefits. Complementing these, a national sample study identified the social determinants of health—housing stability, transportation, income, and social support among them—that predict whether veterans ever initiate evidence-based psychotherapy for PTSD in the first place, a reminder that even the best treatments fail when patients cannot reach them.

Sleep and substance use form a third cluster of studies with strong technical dimensions. The SEDATIVE trial tested a novel parallel-delivery model in which clinical pharmacists led deprescribing of sleep medications while patients simultaneously received clinician-supervised asynchronous cognitive behavioral therapy for insomnia, an arrangement designed to reduce reliance on sedative-hypnotics whose long-term risks are increasingly recognized. Substance use research in the issue spans both epidemiology and intervention: national data show ongoing trends in substance use disorder diagnoses among veterans across a decade, contingency management—the systematic reinforcement of drug-free specimens—has been implemented at scale across the VA with measurable effects on attendance and substance use outcomes, and qualitative work in highly rural-serving VA hospitals documents veterans’ own views on alcohol use, their experiences of alcohol withdrawal syndrome treatment, and the pathways into subsequent alcohol use disorder care. A study of US Army Reserve and National Guard soldiers found that motherhood status exerted a protective effect on alcohol use relative to civilian women, complicating simple narratives about military service and drinking.

Digital health and telehealth innovations constitute perhaps the most forward-looking portion of the issue. A systematic review evaluated digital interventions targeting the impact of stress on stress-related mental health outcomes in military personnel and veterans, aggregating evidence across a rapidly proliferating landscape of apps and web-based programs. Implementation studies examined outcomes for virtual mental health care delivered to rural Native veterans, a population for whom geographic isolation, cultural factors, and historical mistrust of mainstream institutions create layered barriers to care. Qualitative research explored veterans’ needs and perceptions regarding telemental healthcare among veterans with spinal cord injuries, a group whose mobility limitations make remote care especially consequential. Additional work on tobacco and nicotine cessation assessed the implications for Area Health Education Centers, and a pilot study described the development, implementation, and acceptability of an acceptance and commitment therapy-based intervention aimed at promoting brain health in older veterans, extending behavioral medicine into the realm of cognitive aging.

Peer support and whole-health models round out the collection’s care-innovation themes. A mixed methods two-phase pilot study evaluated peer support for whole health, testing whether veterans trained as peers can help fellow veterans engage with self-management, prevention, and wellness-oriented goals. This work connects to the VA’s broader Whole Health System, which has integrated complementary and integrative health approaches into conventional care and represents one of the largest experiments in person-centered medicine anywhere in American health care. The editors place these innovations in a long historical arc: behavioral principles entered federal veteran care as early as the 1950s, when psychologists developed programs in tuberculosis hospitals serving veterans, and the field has since grown into a discipline that spans psychotherapy, health behavior change, technology-mediated care, and systems engineering.

What unifies the twenty articles, the editors argue, is a shared recognition that improving veterans’ health requires acting simultaneously at multiple levels. Addressing social and structural determinants of health, expanding access to evidence-based interventions, and deploying innovative models of care—telehealth, digital therapeutics, peer support, pharmacist-led deprescribing, and implementation science methods that systematically close the gap between what is known and what is delivered—are presented not as alternatives but as complementary strategies. The special issue’s call for papers had explicitly invited work on resilience, posttraumatic growth, and strengths-based research alongside deficit-focused studies, and the resulting collection reflects that balance, treating veterans not merely as carriers of risk but as people whose families, communities, and life courses shape and are shaped by their health. For a population whose service produces obligations that extend across generations, the editors conclude, behavioral medicine is positioned to be both the science of that burden and the source of its relief.

Subject of Research: Behavioral medicine research on the mental and physical health of military veterans

Article Title: Military veterans and behavioral medicine: introduction to the special issue

Article References: Military veterans and behavioral medicine: introduction to the special issue. (n.d.). https://doi.org/10.1007/s10865-026-00706-x

Image Credits: AI Generated

DOI: 10.1007/s10865-026-00706-x

Keywords: military veterans, behavioral medicine, PTSD, suicide prevention, chronic pain, telehealth, digital therapeutics, peer support, implementation science, military-to-civilian transition, chronic disease self-management, sleep disorders